NEW YORK (TheStreet) -- Shares of Mylan (MYL) - Get Report were gaining 4.6% to $57.85 Wednesday after the drug company announced the U.S. launch of several drugs.

Mylan announced the launch of Buprenorphine Hydrochloride Sublingual Tablets, 2 mg and 8 mg, a generic version of Reckitt Benckiser's  (RBGLY)  Subutex Sublingual Tablets following approval from the FDA. The drug is intended to help treat opioid dependence, according to the company.

The company also announced the U.S. launch of Disulfiram Tablets USP, 250 mg and 500 mg, a generic version of Odyssey Pharmaceutical's Antabuse. The drug is meant as "an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to the best advantage," according to Mylan.

Mylan also announced the U.S. launch of its Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr. The launch makes Mylan the only company to offer eight Fentanyl Transdermal System dosage strengths, in addition to its current offerings of Fentanyl Transdermal System 12, 25, 50, 75 and 100 mcg/hr.

TheStreet Ratings team rates MYLAN NV as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:

"We rate MYLAN NV (MYL) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, increase in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

• The revenue growth came in higher than the industry average of 10.4%. Since the same quarter one year prior, revenues rose by 15.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
• Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Pharmaceuticals industry and the overall market, MYLAN NV's return on equity significantly exceeds that of both the industry average and the S&P 500.
• The net income growth from the same quarter one year ago has significantly exceeded that of the Pharmaceuticals industry average, but is less than that of the S&P 500. The net income increased by 5.0% when compared to the same quarter one year prior, going from $180.23 million to $189.20 million.
• MYLAN NV's earnings per share improvement from the most recent quarter was slightly positive. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, MYLAN NV increased its bottom line by earning $2.34 versus $1.58 in the prior year. This year, the market expects an improvement in earnings ($4.15 versus $2.34).
• You can view the full analysis from the report here: MYL Ratings Report